News & Updates

Treatment with etranacogene dezaparvovec demonstrates efficacy with a favourable safety profile in a subset of adult patients with severe or moderately severe haemophilia B living with HIV, according to a recent study presented at ASH 2023.

Infants with human nonpolio enterovirus (EV) central nervous system (CNS) infection often present without cerebrospinal fluid (CSF) pleocytosis, reports a study.

Patients with type 1 diabetes (T1D) who have been vaccinated against COVID-19 do not appear to have worsened glycaemic control, according to a study.

Coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv) and the seasonal influenza vaccine (SIV) offers protection against the two infections, with an efficacy that is similar as when giving each vaccine alone, according to a study.

New drug applications approved by US FDA as of 16-30 November  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Initiating antiretroviral therapy (ART) within 48 hours of life for infants born with HIV can lead to sustained viral suppression, as reflected by reduced HIV reservoirs by age 2 years, which suggests the possibility of an ART-free remission.